UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response...

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)																
Name and Address of Reporting Person * Oliviero James F III				2. Issuer Name and Ticker or Trading Symbol Checkpoint Therapeutics, Inc. [CKPT]							5	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last) (First) (Middle) 2 GANSEVOORT ST, 9TH FLOOR				3. Date of Earliest Transaction (Month/Day/Year) 02/24/2020								X Officer (give title below) Other (specify below) CEO, President and Director						
(Street) NEW YORK, NY 10014				4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person						
(City) (State) (Zip)				Table I - Non-Derivative Securities Acqui							cquir	ired, Disposed of, or Beneficially Owned						
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if r) any (Month/Day/Year		Code		on	4. Securities Acquires (A) or Disposed of (E) (Instr. 3, 4 and 5)			of (D)			Following	Form: Direct (D)	7. Nature of Indirect Beneficial Ownership	
							Code		Amour		(A) or (D)	Price				or Indirect (I) (Instr. 4)	(Instr. 4)	
COMMON STOCK (RESTRICTED)		02/24/2020				A			598,00 (1)	00 A	A	\$ 0	2,733,000 (2)			D		
			Table II - D					cquired	ontai ne for , Disp	ned in the median of the media	this lays	form a cu Benef	n are urren ficially	not requ tly valid		ormation spond unle trol numbe	ss	1474 (9-02)
1. Title of Derivative Conversion Date Execution Conversion (Month/Day/Year)		3A. Deemed Execution Date	e, if	4. Transacti Code	5 ion N C C C C C C C C C C C C C C C C C C	varrants, opt 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		e	•		8. Price of Derivative Security (Instr. 5)	9. Number Derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Owners Form o Derivat Securit Direct (or India	f Benefici ive Ownersl (y: (Instr. 4)		
Renor	ting ()	wners																

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Oliviero James F III 2 GANSEVOORT ST, 9TH FLOOR NEW YORK, NY 10014	X		CEO, President and Director				

Signatures

/s/ James F. Oliviero, III	02/25/2020	
**Signature of Reporting Person	Date	

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares of restricted stock vest as follows: one-half on February 24, 2022, one-fourth on February 24, 2023, and one-fourth on February 24, 2024.
- (2) Includes shares of restricted Common Stock, which vest over various time periods.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.